This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate the basal and spiked TEG® (Thromboelastography) or ROTEM® (Thromboelastometry) profiles of frequently bleeding haemophilia subjects with inhibitors in a non-bleeding state.

The TEG parameters are: R time (Reaction Time), K time (K Time (arbitrary measurement)), a (a angle), MA (Maximum Amplitude) and LY30 (Lysis 30 min after MA) while the ROTEM parameters are: CT (Clotting Time), CFT (Clot Formation Time), a (a angle), MCF (Maximum Clot Firmness) and LI60 (Lysis index 60 min after CT)

Inclusion Criteria:

• Confirmed diagnosis of congenital haemophilia A or B with a FVIII:C clot activity or FIX:C clot activity, respectively, less than 5%
• Presently use of activated recombinant human factor VII (NovoSeven®) as haemostatic agent for preventive treatment or treatment of bleeding episodes
• A documented historical or present record for the presence of inhibitors to factor VIII or IX, respectively
• A documented history of 2 or more joint bleeding episodes during the preceding 12 months
• Subjects must be in a non-bleeding state (i.e. no clinical manifestations of active bleeds)

Exclusion Criteria:

• Subjects who have received any haemostatic treatment for a bleeding episode within the last 7 days prior to this trial
• Immune tolerance therapy within the last 30 days prior to this trial
• Clinically relevant coagulation disorders other than congenital haemophilia A or B
• Thrombocytopenia (platelet count below 60,000 platelets/mcl)
• Prophylactic haemostatic treatment within 3 days prior to this trial